OBJECTIVE: To summarize the randomized evidence regarding the association between acyclovir use and HIV-1 replication as measured by plasma HIV-1 RNA viral load among individuals coinfected with herpes simplex virus (HSV)-2. DESIGN: Meta-analysis of seven randomized trials conducted between 2000 and 2009. Inclusion criteria composed of acyclovir or valacyclovir use as prophylaxis among individuals coinfected with HIV-1 and HSV-2 who were ineligible for highly active antiretroviral therapy. HIV-1 viral load was the outcome. METHODS: Random-effects summarization was used to combine treatment effect estimates. Stratified and meta-regression analyses were used to compare estimated treatment effects by characteristics of trials and participants. RESULTS: The summary treatment effect estimate was -0.33 (95% confidence interval: -0.56, -0.10, 95% population effects interval: -0.74, 0.08) log(10) copies, an approximate halving of plasma viral load. However, there was marked heterogeneity (P < 0.001). Older median age, valacyclovir, higher compliance, earlier publication, and shorter study length were associated with a larger decrease in viral load as compared with their counterparts. CONCLUSION: Current evidence suggests a range of favorable effects of acyclovir on plasma HIV-1 viral load among persons coinfected with HSV-2.
OBJECTIVE: To summarize the randomized evidence regarding the association between acyclovir use and HIV-1 replication as measured by plasma HIV-1 RNA viral load among individuals coinfected with herpes simplex virus (HSV)-2. DESIGN: Meta-analysis of seven randomized trials conducted between 2000 and 2009. Inclusion criteria composed of acyclovir or valacyclovir use as prophylaxis among individuals coinfected with HIV-1 and HSV-2 who were ineligible for highly active antiretroviral therapy. HIV-1 viral load was the outcome. METHODS: Random-effects summarization was used to combine treatment effect estimates. Stratified and meta-regression analyses were used to compare estimated treatment effects by characteristics of trials and participants. RESULTS: The summary treatment effect estimate was -0.33 (95% confidence interval: -0.56, -0.10, 95% population effects interval: -0.74, 0.08) log(10) copies, an approximate halving of plasma viral load. However, there was marked heterogeneity (P < 0.001). Older median age, valacyclovir, higher compliance, earlier publication, and shorter study length were associated with a larger decrease in viral load as compared with their counterparts. CONCLUSION: Current evidence suggests a range of favorable effects of acyclovir on plasma HIV-1 viral load among persons coinfected with HSV-2.
Authors: Jairam R Lingappa; Jared M Baeten; Anna Wald; James P Hughes; Katherine K Thomas; Andrew Mujugira; Nelly Mugo; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; James Kiarie; Carey Farquhar; Grace John Stewart; Joseph Makhema; Myron Essex; Edwin Were; Kenneth H Fife; Guy de Bruyn; Glenda E Gray; James A McIntyre; Rachel Manongi; Saidi Kapiga; David Coetzee; Susan Allen; Mubiana Inambao; Kayitesi Kayitenkore; Etienne Karita; William Kanweka; Sinead Delany; Helen Rees; Bellington Vwalika; Amalia S Magaret; Richard S Wang; Lara Kidoguchi; Linda Barnes; Renee Ridzon; Lawrence Corey; Connie Celum Journal: Lancet Date: 2010-02-12 Impact factor: 79.321
Authors: Moira A McMahon; Janet D Siliciano; Jun Lai; Jun O Liu; James T Stivers; Robert F Siliciano; Rahul M Kohli Journal: J Biol Chem Date: 2008-09-24 Impact factor: 5.157
Authors: W A O'Brien; P M Hartigan; D Martin; J Esinhart; A Hill; S Benoit; M Rubin; M S Simberkoff; J D Hamilton Journal: N Engl J Med Date: 1996-02-15 Impact factor: 91.245
Authors: Richard A Zuckerman; Aldo Lucchetti; William L H Whittington; Jorge Sánchez; Robert W Coombs; Amalia Magaret; Anna Wald; Lawrence Corey; Connie Celum Journal: AIDS Date: 2009-02-20 Impact factor: 4.177
Authors: Clare Tanton; Helen A Weiss; Mary Rusizoka; Jerome Legoff; John Changalucha; Kathy Baisley; Kokugonza Mugeye; Dean Everett; Laurent Belec; Tim C Clayton; David A Ross; Richard J Hayes; Deborah Watson-Jones Journal: J Infect Dis Date: 2010-05-01 Impact factor: 5.226
Authors: Christophe Vanpouille; Andrea Lisco; Andrea Introini; Jean-Charles Grivel; Arshi Munawwar; Melanie Merbah; Raymond F Schinazi; Marco Derudas; Christopher McGuigan; Jan Balzarini; Leonid Margolis Journal: Antimicrob Agents Chemother Date: 2012-02-06 Impact factor: 5.191
Authors: Pragna Patel; Tim Bush; Kenneth H Mayer; Sheila Desai; Keith Henry; Edgar Turner Overton; Lois Conley; John Hammer; John T Brooks Journal: Sex Transm Dis Date: 2012-02 Impact factor: 2.830
Authors: Steven J Reynolds; Fred Makumbi; Kevin Newell; Noah Kiwanuka; Paschal Ssebbowa; George Mondo; Iga Boaz; Maria J Wawer; Ronald H Gray; David Serwadda; Thomas C Quinn Journal: Lancet Infect Dis Date: 2012-03-19 Impact factor: 25.071
Authors: Christophe Vanpouille; Andrea Lisco; Jean-Charles Grivel; Leda C Bassit; Robert C Kauffman; Jorge Sanchez; Raymond F Schinazi; Michael M Lederman; Benigno Rodriguez; Leonid Margolis Journal: Clin Infect Dis Date: 2015-03-03 Impact factor: 9.079